Stay updated on Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.

Latest updates to the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision history updated: added v3.3.2 and removed v3.2.0; no changes to the study content.SummaryDifference0.0%

- Check27 days agoChange DetectedRemoved the government funding lapse notice from the page. The study details and related information remain unchanged.SummaryDifference0.3%

- Check35 days agoChange DetectedThe page now displays sponsor-related entries such as the H. Lee Moffitt Cancer Center and Research Institute and includes a 'Helpful Links Provided by' section with a link to the Moffitt Clinical Trials site. This enhances access to sponsor resources and related trial information on the study page.SummaryDifference0.1%

- Check42 days agoChange DetectedNo significant changes to the study details were detected between versions; any differences are likely cosmetic formatting or layout adjustments. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check63 days agoChange DetectedUpdate introduces newer date stamps and an estimated last-update label, while removing older date references and a prior last-update cue.SummaryDifference0.4%

- Check71 days agoChange DetectedUpgrade to version v3.2.0 with an operational status notice about potential delays and updated links; replaces the previous v3.1.0 reference.SummaryDifference2%

Stay in the know with updates to Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab/Ipilimumab/Nintedanib Combo in NSCLC Clinical Trial page.